Binding of CD16 agonist anti-CD16 antibody on NK cells is capable of triggering NK cell activation that results in NK cell cytotoxic activity against cancer cells and releasing of cytokines, such as interferon γ (IFNγ) [25, 26]. This evidence concerns the gene FCGR3A and cancer.